Sagimet Biosciences Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Sagimet Biosciences Inc. (SGMT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $130.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-11
- Sagimet Biosciences Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $101.64M, a 734.47% increase year-over-year.
- Sagimet Biosciences Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $12.18M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $130.88M 10-Q · filed 2026-08-11 | ||||
| 2025-12-31 | $1.60M 10-Q · filed 2026-05-12 | -$40.82M 10-K · filed 2026-03-11 | |||
| 2025-06-30 | -$33.51M 10-Q · filed 2026-08-11 | ||||
| 2024-12-31 | -$11.12M 10-Q · filed 2026-05-12 | $701.00K 10-K · filed 2025-03-12 | |||
| 2024-06-30 | $20.82M 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | $101.64M 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $1.88M 10-Q · filed 2025-11-13 | $74.98M 10-K · filed 2024-03-25 | |||
| 2023-09-30 | $101.68M 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | $18.35M 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | $12.18M 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $101.68M 10-Q · filed 2024-11-14 | -$56.57M 10-K · filed 2024-03-25 | |||
| 2022-09-30 | -$54.50M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$52.27M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |